{"product_id":"valneva-marketing-mix","title":"Valneva Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Valneva’s vaccine-focused product portfolio, pricing tactics, targeted distribution channels, and scientific promotion work together to build market trust and commercial traction—this preview only scratches the surface; purchase the full 4P’s Marketing Mix Analysis for a presentation-ready, editable report filled with data-driven insights and actionable recommendations to accelerate your strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIXCHIQ Chikungunya Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIXCHIQ, the first licensed chikungunya vaccine, is Valneva's flagship product targeting travelers and residents in high-risk regions; by Dec 2025 it reported \u0026gt;150,000 doses distributed across North America and Europe and generated €120m in revenue in FY2025.\u003c\/p\u003e\n\u003cp\u003eRegulatory expansion included approvals in the US, EU, Canada, and five additional markets by late 2025, supporting a projected market reach of ~80 million at-risk individuals.\u003c\/p\u003e\n\u003cp\u003eThe single-dose regimen offers rapid protection and a clear convenience advantage for pre-travel immunization, shortening protection timelines versus multi-dose competitors and reducing administration costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIXIARO Japanese Encephalitis Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIXIARO drives a large share of Valneva’s 2025 vaccine revenue, with JE vaccine sales reported at €92m in 2024 and remaining the only Japanese encephalitis vaccine approved for US and EU travelers.\u003c\/p\u003e\n\u003cp\u003eThe vaccine is mission-critical for militaries and long-term travelers to Asia\/Western Pacific; WHO estimates 68,000 clinical JE cases annually, keeping demand stable.\u003c\/p\u003e\n\u003cp\u003eValneva has invested in manufacturing upgrades and buffer inventory to target \u0026gt;95% on-time supply and reduce batch failures below 1%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDUKORAL Cholera and ETEC Vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDUKORAL is an oral vaccine preventing cholera and, in some countries, enterotoxigenic E. coli (ETEC) diarrhea; Valneva sold ~€18m of travel-vaccine revenue in 2024, with DUKORAL a core SKU for travelers to high-risk areas. Targeted mainly at tourists, aid workers, and military personnel visiting low-sanitation regions, uptake rose 6% in 2024 as travel recovered. Its well-documented safety and single-dose oral administration keep it standard in travel clinics and pharmacy travel-kits worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVLA15 Lyme Disease Candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVLA15, developed with Pfizer, is the only Lyme vaccine candidate in late-stage (Phase 3) development as of 2025 and could be Valneva’s primary growth driver if trials succeed.\u003c\/p\u003e\n\u003cp\u003ePhase 3 focus targets prevention across Borrelia species amid rising Northern Hemisphere tick-borne cases—CDC reports ~476,000 US Lyme diagnoses annually (2016–2020 estimate); EU incidence rising in several countries.\u003c\/p\u003e\n\u003cp\u003ePositive Phase 3 results would unlock major market value: addressable US\/EU market \u0026gt;$2–3 billion annually by conservative estimates given case load and vaccine pricing scenarios.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnly late-stage Lyme vaccine (Phase 3) in 2025\u003c\/li\u003e\n\u003cli\u003eDeveloped with Pfizer; co-development agreement\u003c\/li\u003e\n\u003cli\u003eCDC estimate ~476,000 US diagnoses\/year (2016–2020)\u003c\/li\u003e\n\u003cli\u003eEstimated US\/EU addressable market $2–3B\/yr\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Vaccine Pipeline Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva invests in R\u0026amp;D for Zika and other emerging diseases, advancing early-stage candidates on its inactivated and Vero-cell platforms to cut development risk.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, R\u0026amp;D spend was €78.4m (2024 FY), supporting pipeline progression and targeting markets with \u0026gt;50% unmet need where incumbents are weak.\u003c\/p\u003e\n\u003cp\u003eThe pipeline strategy aims to deliver a steady stream of specialty vaccines to sustain revenue growth and long-term competitiveness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€78.4m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: Zika + emerging diseases\u003c\/li\u003e\n\u003cli\u003ePlatform: inactivated, Vero-cell\u003c\/li\u003e\n\u003cli\u003eTargets high unmet-need markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: IXCHIQ drives €120M 2025, IXIARO €92M, VLA15 Phase‑3 with $2–3B upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIXCHIQ: flagship chikungunya vaccine—\u0026gt;150,000 doses distributed by Dec 2025; €120m FY2025 revenue; approvals US\/EU\/CA+5 markets; single-dose convenience. IXIARO: JE vaccine €92m 2024; mission-critical for military\/travelers. DUKORAL: €18m travel vaccines 2024. VLA15: Phase 3 (with Pfizer), US\/EU addressable $2–3B\/yr if successful. R\u0026amp;D €78.4m (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXCHIQ\u003c\/td\u003e\n\u003ctd\u003e150k doses; €120m (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXIARO\u003c\/td\u003e\n\u003ctd\u003e€92m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDUKORAL\u003c\/td\u003e\n\u003ctd\u003e€18m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVLA15\u003c\/td\u003e\n\u003ctd\u003ePhase 3; $2–3B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€78.4m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Valneva’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context to inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Valneva’s 4P marketing analysis into a concise, at-a-glance summary that eases leadership briefings and rapid alignment, enabling quick customization for decks, team workshops, or competitive comparisons while helping non-marketers grasp the company’s strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Travel Health Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva sells mainly through specialized travel clinics and vaccination centers, which in 2024 delivered about 62% of its commercial vaccine volumes in Europe, targeting affluent travelers who pay privately or use premium insurers.\u003c\/p\u003e\n\u003cp\u003eThese clinics provide expert pre-travel consultations and preventative vaccines, matching Valneva’s premium pricing—its VLA15 list pricing near €75–€90 per dose in 2024—so stock placement drives higher ASPs (average selling prices).\u003c\/p\u003e\n\u003cp\u003eConcentrating distribution in ~3,200 niche clinics across key markets (UK, France, Germany) ensures product availability where wealthy international travelers book, increasing conversion and lowering broad-channel marketing spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Pfizer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor its Lyme disease vaccine candidate, Valneva uses Pfizer’s global commercial network—Pfizer has 2024 revenue of $58.7B—to secure distribution and scale manufacturing capacity beyond Valneva’s 2024 €264M revenue footprint.\u003c\/p\u003e\n\u003cp\u003eThe deal opens access to North America and Europe channels where Pfizer’s logistics cover 175+ markets and cold-chain capacity that Valneva alone could not match.\u003c\/p\u003e\n\u003cp\u003eOnce approvals arrive, the partnership materially de-risks launch costs and speeds uptake, aiming for multi-million dose rollouts and higher market penetration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilitary and Government Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva holds multi-year supply agreements with government bodies, notably the US Department of Defense, for IXIARO, securing predictable revenue—IXIARO represented about 18% of 2024 product sales (€56m of €310m). These institutional channels deliver large, stable volumes for troops and contractors deployed to high-risk regions, supporting production planning and cash flow forecasting. Long-term contracts reduce sales volatility and improve capacity utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Wholesale and Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvalneva uses established pharmaceutical wholesalers to distribute vaccines from its production sites hospitals and retail pharmacies ensuring broad availability for products like dukoral prescribed by general practitioners in valneva reported vaccine revenues of with wholesale channels handling doses shipped.\u003e\n\u003cpefficient cold-chain logistics are maintained through certified refrigerated transport and temperature-monitoring reducing spoilage rates average for well-managed vaccine supply chains valneva invests in distribution quality controls.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWholesale channels cover ~70% of shipments\u003c\/li\u003e\n\u003cli\u003e2024 vaccine revenue €204m\u003c\/li\u003e\n\u003cli\u003eCold-chain spoilage \u0026lt;2% with monitoring\u003c\/li\u003e\n\u003cli\u003eDistribution QA spend ≈€8m\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pefficient\u003e\u003c\/pvalneva\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvalneva uses licensing and distribution deals with local partners like instituto butantan to enter low-infrastructure markets easing regulatory navigation cold-chain gaps so ixchiq can reach endemic regions in such partnerships supported access estimated million additional doses latin america.\u003e\n\u003cpthese agreements lower market entry cost and risk speed rollout leverage local manufacturing or distribution revenue-sharing deals typically range from royalties improving coverage without large capex.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner: Instituto Butantan—local registration, distribution\u003c\/li\u003e\n\u003cli\u003eImpact: ~1–2M extra IXCHIQ doses (2024 estimate)\u003c\/li\u003e\n\u003cli\u003eEconomics: ~10–25% royalty bands\u003c\/li\u003e\n\u003cli\u003eBenefit: faster regulatory approval and wider endemic reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pvalneva\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: Niche travel-clinic leader with €56m IXIARO, strong wholesale \u0026amp; QA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s place strategy mixes niche travel clinics (62% EU volumes, ~3,200 sites), wholesalers (~70% shipments), institutional contracts (IXIARO €56m in 2024) and partner networks (Pfizer for Lyme, Instituto Butantan in LATAM), backed by cold-chain QA (~€8m\/yr, spoilage \u0026lt;2%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 %\/€\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTravel clinics\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXIARO sales\u003c\/td\u003e\n\u003ctd\u003e€56m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution QA\u003c\/td\u003e\n\u003ctd\u003e€8m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eValneva 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Valneva 4P's Marketing Mix document you’ll receive instantly after purchase—complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750778024313,"sku":"valneva-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/valneva-marketing-mix.png?v=1772226290","url":"https:\/\/growthsharematrix.com\/products\/valneva-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}